Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.

Microbot Medical Inc.

Israeli Ministry of Health's AMAR Division grants marketing clearance for LIBERTY Endovascular Robotic System in Israel.
First regulatory approval outside the U.S.; enables Free Sale Certificate for submissions in other jurisdictions.
Company targets CE Mark certification by end of 2026 for EU market expansion.
System adopted by multiple U.S. accounts in GA, FL, NY, MA, MI, NC.
Advanced discussions underway to expedite commercialization in Israel.

item 7.01 item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #5 for 2026-05-26. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-025171
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2026-05-26T12:30:22+00:00
discovered_at: 2026-05-26T12:35:03.485223+00:00
generated_at: 2026-05-26T12:35:18.868478+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-025171
json_url: https://secwatch.observer/filing/0001493152-26-025171.json
markdown_url: https://secwatch.observer/filing/0001493152-26-025171.md
text_url: https://secwatch.observer/filing/0001493152-26-025171.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/0001493152-26-025171-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-025171

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.